Abstract | PURPOSE OF REVIEW: Patients with metastatic castration-resistant prostate cancer (CRPC) no longer responsive to docetaxel have a poor prognosis, worsened quality-of-life, and traditionally few options for treatment. This review addresses promising and practice-changing developments for the treatment of CRPC in the second-line setting. RECENT FINDINGS: SUMMARY:
|
Authors | Michael Ong, Eric Winquist |
Journal | Current opinion in supportive and palliative care
(Curr Opin Support Palliat Care)
Vol. 5
Issue 3
Pg. 199-205
(Sep 2011)
ISSN: 1751-4266 [Electronic] United States |
PMID | 21734586
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Androgen Antagonists
- Antineoplastic Agents
|
Topics |
- Androgen Antagonists
(therapeutic use)
- Antineoplastic Agents
(therapeutic use)
- Humans
- Male
- Orchiectomy
- Prognosis
- Prostatic Neoplasms
(drug therapy, psychology, surgery)
- Quality of Life
(psychology)
- Time Factors
- Treatment Failure
|